

June 12, 2026

To whom it may concern:

Company Name: TOHO HOLDINGS CO.,LTD.
 Corporate Representative: Hiromi Edahiro, Representative Director, President and CEO
 (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
 Contact: Makoto Kawamura, Executive Corporate Officer and General Manager, Corporate Strategy Division
 (TEL: 81-3-6838-2803)

Notice Regarding Launch of KYOSOMIRAI PHARMA of
 3 Ingredients / 3 Products of Generic Drugs

TOHO HOLDINGS CO.,LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Yasuyuki Kumada), the wholly-owned subsidiary involved in pharmaceuticals manufacturing and sales business, has launched 3 ingredients / 3 products of generic drugs today on June 12, 2026 as below.

New products list

Classes	Product Name	Original Brand Name
Long-acting selective H1 receptor antagonist Therapeutic agent for allergic disease	Desloratadine Tablets 5mg "Chemiphar"	DESALEX®Tablets 5mg
Therapeutic agent for allergic disease	Bilastine OD Tablets 20mg "DAITO"	Bilanoa®OD tablets
Aromatase inhibition	Letrozole Tablets 2.5mg "Chemiphar"	Femara®Tablets2.5mg

Note: This document has been translated from the Japanese original for reference purposes only.
 In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.